SklCoin: Toward a Scalable Proof-of-Stake and Collective Signature Based Consensus Protocol for Strong Consistency in Blockchain

Abstract Embryonal tumors with multilayer rosettes (ETMR) are rare and highly-aggressive central nervous system (CNS) neoplasms which occur primarily in young children and carry a dismal prognosis. To date, no large clinical investigations have been conducted to determine the optimal therapy for ETMR. Data from retrospective case series suggest that our most aggressive standard therapies are not sufficient for cure in the majority of cases. New treatment approaches incorporating pre-clinical data and the known biology of ETMR are therefore urgently needed. A German drug screen using the patient-derived ETMR BT183 cell line and its xenograft revealed anti-tumor activity of topotecan, doxorubicin, and actinomycin D; three agents used infrequently for treating infant CNS tumors. Additional results from a small series of ETMR patients suggest that optimization of induction chemotherapy using these active agents may improve response and survival outcomes. In 2019, an international panel of pediatric neuro-oncology experts convened to advance therapy for ETMR. A consensus protocol was developed incorporating maximal safe surgical resection, induction chemotherapy with active pre-clinical agents, intrathecal chemotherapy, radiotherapy, and high-dose chemotherapy. This international consensus protocol represents the first prospective clinical investigation specific to ETMR and will be available through a treatment registry globally and as a clinical trial at select centers. The study aims to improve survival by providing aggressive, optimized therapy for ETMR and will serve as a platform to explore new biologically-promising agents. The investigation will also provide valuable prospective outcome data and correlative biological studies to serve as baseline comparators for future clinical trials.

Download Full-text

Determination of α(Mz) from an hyperasymptotic approximation to the energy of a static quark-antiquark pair

Journal of High Energy Physics ◽

10.1007/jhep09(2020)016 ◽

2020 ◽

Vol 2020 (9) ◽

Cited By ~ 3

Author(s):

Cesar Ayala ◽

Xabier Lobregat ◽

Antonio Pineda

Keyword(s):

Perturbation Theory ◽

Energy Range ◽

Short Distance ◽

Weak Coupling ◽

Strong Consistency ◽

Lattice Data ◽

Static Potential ◽

Static Energy ◽

Static Quark

Abstract We give the hyperasymptotic expansion of the energy of a static quark-antiquark pair with a precision that includes the effects of the subleading renormalon. The terminants associated to the first and second renormalon are incorporated in the analysis when necessary. In particular, we determine the normalization of the leading renormalon of the force and, consequently, of the subleading renormalon of the static potential. We obtain $$ {Z}_3^F $$ Z 3 F (nf = 3) = $$ 2{Z}_3^V $$ 2 Z 3 V (nf = 3) = 0.37(17). The precision we reach in strict perturbation theory is next-to-next-to-next-to-leading logarithmic resummed order both for the static potential and for the force. We find that the resummation of large logarithms and the inclusion of the leading terminants associated to the renormalons are compulsory to get accurate determinations of $$ {\Lambda}_{\overline{\mathrm{MS}}} $$ Λ MS ¯ when fitting to short-distance lattice data of the static energy. We obtain $$ {\Lambda}_{\overline{\mathrm{MS}}}^{\left({n}_f=3\right)} $$ Λ MS ¯ n f = 3 = 338(12) MeV and α(Mz) = 0.1181(9). We have also MS found strong consistency checks that the ultrasoft correction to the static energy can be computed at weak coupling in the energy range we have studied.

Download Full-text